EP4 antagonist compounds and their salts, crystal polymorphs and uses

JP2024537564A5Active Publication Date: 2024-11-14WUHAN HUMANWELL INNOVATIVE DRUG RES & DEV CENT LTD CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024513882
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-03
Filing Date
2022-09-02
Publication Date
2024-11-14
Estimated Expiration
2042-09-02

AI Technical Summary

Technical Problem

Current treatments for EP4-related diseases, such as inflammatory diseases, pain, and cancer, often have cardiovascular and gastrointestinal side effects, and there is a need for more targeted and effective therapies that modulate the tumor microenvironment to inhibit tumor progression.

Method used

Development of crystalline forms and pharmaceutically acceptable salts of EP4 antagonist compounds, specifically free acid crystalline forms A and B, and salts like tromethamine, diethylamine, and lysine salts, which are characterized by unique X-ray powder diffraction patterns and thermal properties, enhancing their pharmaceutical stability and solubility.

Benefits of technology

The crystalline forms and salts of EP4 antagonists provide improved pharmaceutical stability, solubility, and reduced hygroscopicity, offering better clinical treatment options for EP4-related diseases with reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates to an EP4 antagonist represented by formula (I), specifically including its crystalline form, pharmaceutically acceptable salt or crystalline form thereof, methods for preparing them, compositions containing them, and pharmaceutical uses of related compounds. The structure of formula I is shown below: [Case 1] JPEG2024537564000027.jpg40169
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] This application claims priority from the applicant's prior application, bearing patent number 202111034159.1 and entitled "EP4 antagonist compounds and their salts, crystalline polymorphs and uses," filed with the State Intellectual Property Office of the People's Republic of China on September 3, 2021, the entire text of which is incorporated herein by reference. [Technical field] The present invention belongs to the pharmaceutical field and relates to an EP4 antagonist compound and its salt, crystal polymorphism, and the preparation method and use thereof. [Background technology] Prostaglandin E2 (PGE2) is an endogenous biologically active lipid that activates prostaglandin receptors, resulting in a wide range of upstream and downstream dependent biological responses (Legler, DF et al, hit. J Biochem. Cell Biol. 2010, 42, p. 198-201), and is involved in the regulation of many physiological and pathological processes, including inflammation, pain, renal function, cardiovascular system, pulmonary function, and cancer. PGE2 has been reported to be highly expressed in cancer tissues of various cancers, and it has been confirmed that PGE2 is correlated with the onset, growth, and progression of cancer and disease states in patients. PGE2 is associated with the activation of cell proliferation and cell death (apoptosis), and is generally believed to play an important role in the processes of cancer cell proliferation, disease progression, and cancer metastasis.

[0002] There are four subtypes of PGE2 receptors, EP1, EP2, EP3 and EP4, which are widely distributed in various tissues. Among these subtypes, PGE2 is involved in inflammatory reactions (including immune inflammatory reactions), smooth muscle relaxation, pain, lymphocyte differentiation, mesangial cell hypertrophy or proliferation, gastrointestinal mucus secretion, etc., via EP4 receptor. Therefore, EP4 receptor antagonists are considered to be promising as anti-inflammatory and / or analgesic agents for treating diseases related to the PGE2-EP4 pathway, such as inflammatory diseases and diseases accompanied by various pains.

[0003] EP4 is the main receptor involved in joint inflammatory pain in rodent models of rheumatoid arthritis and osteoarthritis (see, for example, J. Pharmacol. Exp. Ther., 325, 425 (2008)), and after activation, it leads to the accumulation of the intracellular signal molecule cAMP. Studies have detected the expression of EP4 receptors in peripheral nerve endings, macrophages and neutrophils of pain receptors, proving that these cell types are crucial for endometriosis. Studies have reported that oral EP4 antagonists can reduce proteinuria and inhibit the progression of diabetic nephropathy in type 2 diabetic mice. Another study has reported that activation of EP4 and increased PGE2 production in the bladder mucosa are important causes of prostatitis causing overactive bladder, and intravesical injection of EP4 antagonists can effectively improve overactive bladder after prostatitis. Therefore, selective EP4 antagonists can be used to treat arthritis pain and arthritis, including endometriosis, diabetic nephropathy, and overactive bladder. Existing arthritis treatments are mainly conventional NSAIDs (nonsteroidal anti-inflammatory drugs) or selective COX-2 inhibitors, which may cause cardiovascular and / or gastrointestinal side effects. Selective EP4 antagonists are less likely to cause cardiovascular side effects.

[0004] PGE2 persistently activates EP receptors (produced in large quantities by tumor cells) in the tumor microenvironment (Ochs et al, J Neurochem. 2016, 136, p. 1142-1154; Zelenay, S. et al, Cell 2015, 162, p. 1257-1270), promoting the accumulation and enhancing the activity of multiple types of immune suppressor cells, including tumor-associated macrophages type 2 (TAMS), Treg cells, and myeloid-derived suppressor cells (MDSCs). One of the main features of the immune suppressive tumor microenvironment is the abundance of MDSCs and TAMs, which are closely correlated with the overall survival of patients with gastric, ovarian, breast, bladder, hepatocellular carcinoma (HCC), head and neck cancer, and other types of cancer. Besides, PGE2 has been reported to induce immune tolerance by inhibiting the accumulation of antigen-presenting dendritic cells (DCs) in tumors and inhibiting the activation of tumor-infiltrating DCs (Wang et al, Trends in Molecular Medicine 2016, 22, p. 1-3). All of these PGE2-mediated effects jointly aid in the escape of tumor cells from immune surveillance. PGE2 plays a crucial role in promoting tumor development and progression. Increased expression levels of PGE2 and its related receptors EP2, EP4 have been found in various malignant tumors, such as colon cancer, lung cancer, breast cancer, and head and neck cancer, and are often closely correlated with poor prognosis (Bhooshan, N .et al. Lung Cancer 101, 88-91). Therefore, selectively blocking the EP2 and EP4 signaling pathways can inhibit tumor development and progression by altering the tumor microenvironment and regulating tumor immune cells.

[0005] Current preclinical research data shows that EP2 and EP4 specific antagonists can prevent or inhibit tumor growth to different degrees in animal models of colon cancer, esophageal cancer, lung cancer and breast cancer. Among the PGE2 receptor drugs that have entered clinical practice, the EP4 antagonist Grapiprant developed by Pfizer has been approved by the FDA for the treatment of canine arthritis, and at the same time, in 2015, it entered an antitumor clinical phase II study for the treatment of multiple solid tumors such as prostate cancer, non-small cell lung cancer and breast cancer (De Vito, V. et al. J Pharm Biomed Anal 118, 251-258). The EP4 antagonist E7046 developed by Eisai Co., Ltd. has developed a related clinical phase I study in 2015 and a phase Ib clinical measurement for the treatment of rectal cancer with combined radiotherapy or chemotherapy in 2017. ONO-4578, developed by Ono Pharmaceutical, is undergoing Phase I clinical studies for advanced or metastatic solid tumors in 2017, and Phase I / II clinical studies as a single agent or in combination with nivolumab to treat advanced solid tumors in 2018.

[0006] Chinese patent application CN202110240347.3 discloses the structure of formula I:

[0007] [ka]

[0008] The compound of formula I can effectively antagonize EP4 receptor activity and has the potential for wide application in the manufacture of therapeutic agents for EP4-related diseases. Therefore, further study of the compound of formula I and its salt crystal forms and crystal forms is of great significance for the development of effective therapeutic agents. [Summary of the Invention] To solve the problems existing in the prior art, according to one aspect, the present invention provides a crystalline form of a compound of formula I, the structure of which is shown below.

[0009] [ka]

[0010] In some embodiments, the present invention provides a free acid crystalline form A of the compound of formula I, wherein the free acid crystalline form A has an X-ray powder diffraction pattern expressed at diffraction angles 2θ±0.2° having diffraction peaks at 7.88, 11.00, 12.13, 16.10, 19.75, 20.65, 21.04, 22.92, 23.53, and 26.69; or The free acid crystalline form A has diffraction peaks at 7.88, 8.08, 11.00, 12.13, 16.10, 19.75, 20.65 and 23.53, and further has an X-ray powder diffraction pattern represented by diffraction angles of 2θ±0.2° at 7.88, 8.08, 11.00, 12.13, 13.59, 15.50, 16.10, 19.44, 19.75, 20.65, 21.04, 22.92, 23.53, 25.32, 26.44, and further, the X-ray powder diffraction pattern of the free acid crystalline form A, expressed as diffraction angles of 2θ±0.2°, is 7.88, 8.08, 10.31, 10.49, 11.00, 11.46, 12.13, 12.82, 13.59, 15.29, 15.50, 15.72, 16.10, 18.27, 18.70, 19.04, 19.44, 19.75, 20.65, 21.04, 21.62, 21.97. , 22.27, 22.92, 23.53, 24.22, 25.32, 25.81, 26.21, 26.44, 26.69, 27.67, 28.99, 29.35, 30.17, 31.12, 31.65, 32.18, 33.44, 33.97, 35.78, 36.84, 37.18 and 37.99, and further wherein the free acid crystalline form A has an XRPD pattern essentially as shown in FIG. 1.

[0011] In some embodiments, the free acid crystalline form A has (1) The TGA curve of the free acid crystalline form A has a weight loss of about 0-2%, preferably about 0-1% (e.g., 0.84%) at 150.0±3° C. (2) The DSC curve for the free acid crystalline form A has an endothermic peak at 134.0±3°C. (3) The DSC curve of the free acid crystalline form A has one, two or three features, such as an endothermic peak at 136.8±3°C.

[0012] In some embodiments, the free acid crystalline form A has (1) The TGA curve of the free acid crystalline form A has a weight loss of about 0.84% ​​at 150.0±3°C; (2) The DSC curve for the free acid crystalline form A has an endothermic peak at 134.0±3°C. (3) The DSC curve of the free acid crystalline form A has one, two or three features, such as an endothermic peak at 136.8±3°C.

[0013] In some embodiments, the TGA pattern of the free acid crystalline form A is shown in FIG. 2, the DSC pattern of the free acid crystalline form A is shown in FIG. 1 The 1 H NMR spectrum is shown in FIG.

[0014] In some embodiments, the present invention provides free acid crystalline form B of the compound of formula I, wherein the free acid crystalline form B has an X-ray powder diffraction pattern expressed at angles 2θ±0.2° having diffraction peaks at 7.38, 8.91, 11.07, 17.85, 18.52, 19.38, 23.05, 26.01, 26.76; and further, the free acid crystalline form B has an X-ray powder diffraction pattern expressed at angles 2θ±0.2° having diffraction peaks at 7.38, 8.91, 11.07, 12.01, 17.85, 18.52, 19.38, 23.05, 26.01, 26.76; and further, the free acid crystalline form B has an X-ray powder diffraction pattern expressed at angles 2θ±0.2° having diffraction peaks at 5.56, 6.00, 7.38, 8.91, 11.07, 12.01, 17.85, 18.52, 19.38, 23.05, 26.01, 26.76. , 11.07, 11.58, 12.01, 13.58, 14.16, 14.78, 17.85, 18.52, 19.38, 22.33, 23.05, 24.64, 26.01, and 26.76, and further, the X-ray powder diffraction pattern of the free acid crystalline form B, expressed as diffraction angles of 2θ±0.2°, has peaks at 5.56, 6.00, 7.3 5.5, 8.27, 8.91, 11.07, 11.58, 12.01, 13.58, 14.16, 14.78, 15.73, 17.85, 18.52, 19.38, 22.33, 23.05, 24.64, 26.01, 26.76, and further wherein the free acid crystalline form B has an XRPD pattern essentially as shown in FIG.

[0015] According to another aspect, the present invention provides a pharma- ceutically acceptable salt of a compound of formula I above, which may be selected from alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), ammonium salts, or salts formed with organic bases providing a physiologically acceptable cation, such as, for example, salts formed with bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide, betaine, monoethanolamine, caffeine, urea, nicotinamide, isonicotine, dimethylglucosamine, ethylglucosamine, glucosamine, meglumine, lysine, arginine, choline, aqueous ammonia, dicyclohexylamine, 1,6-hexanediamine, ethanolamine, diethanolamine, sarcosine, serinol, trihydroxymethylaminomethane, aminopropylene glycol, tromethamine, diethylamine, imidazole, and the like.

[0016] According to a preferred embodiment of the present invention, the pharma- ceutically acceptable salts of the compound of formula I above are the tromethamine, diethylamine and lysine salts of the compound of formula I.

[0017] According to the embodiment of the present invention, those skilled in the art will understand that when the compound of formula I forms a salt with a base, the molar ratio of the compound of formula I to the base may be 5:1 to 1:5, such as 3:1, 2:1, 1:1, 1:1.5, 1:2, 1:2.5, 1:3. It should be understood that the molar ratio of the compound of formula I to the base is preferably 1:1.

[0018] According to another aspect, the present invention provides a crystalline form of a pharma- ceutically acceptable salt of a compound of formula I above.

[0019] In some embodiments, the present invention provides tromethamine salt crystalline Form A of the compound of formula I, wherein the tromethamine salt crystalline Form A has an X-ray powder diffraction pattern expressed at diffraction angles of 2θ±0.2° having diffraction peaks at 6.03, 9.01, 13.50, 15.06, 18.09, 24.27, and further, the tromethamine salt crystalline Form A has an X-ray powder diffraction pattern expressed at diffraction angles of 2θ±0.2° having diffraction peaks at 6.03, 9.01, 13.50, 15.06, 16.03, 18.09, 24.27, 27.28, 30.39, 36.72, and further, the tromethamine salt crystalline Form A has an XRPD pattern essentially as shown in FIG. 6.

[0020] In some embodiments, the tromethamine salt crystalline form A is (1) The TGA curve of the tromethamine salt crystal form A has a weight loss of about 1.0 to 3.5%, preferably about 2.0 to 3.0% (e.g., 2.41%) at 120.0±3°C. (2) The DSC curve of the tromethamine salt crystalline form A has an endothermic peak at 124.5±3°C. (3) The DSC curve of the free acid crystalline form A has one, two or three features, such as an endothermic peak at 139.2±3° C.

[0021] In some embodiments, the tromethamine salt crystalline form A is (1) The TGA curve of tromethamine salt crystalline form A has a weight loss of about 2.41% at 120.0±3°C; (2) The DSC curve of the tromethamine salt crystalline form A has an endothermic peak at 124.5±3°C. (3) The DSC curve of the free acid crystalline form A has one, two or three features, such as an endothermic peak at 139.2±3° C.

[0022] In some embodiments, the TGA pattern of the tromethamine salt crystalline form A is shown in FIG. 7, the DSC pattern of the tromethamine salt crystalline form A is shown in FIG. 1 The 1 H NMR spectrum is shown in FIG.

[0023] In some embodiments, the present invention provides a diethylamine salt crystalline form A of the compound of formula I, wherein the diethylamine salt crystalline form A has diffraction peaks at 5.29, 9.79, 10.53, 18.30, 19.61, 19.99, 21.10, 25.33 and 26.45 in an X-ray powder diffraction pattern expressed at diffraction angles of 2θ±0.2°; and further, the diethylamine salt crystalline form A has diffraction peaks at 5.29, and further, the diethylamine salt crystalline form A has an XRPD pattern essentially as shown in FIG. 10.

[0024] In some embodiments, the diethylamine salt crystalline form A is (1) The TGA curve of the diethylamine salt crystalline form A has a weight loss of about 0.50-3.00%, preferably about 1.00-2.50% (e.g., 1.80%) at 100.0±3°C, and a weight loss of about 2.00-5.00%, preferably about 3.00-4.50% (e.g., 3.99%) at 210.0±3°C. (2) The DSC curve of the diethylamine salt crystalline form A has one or two characteristics, that is, the DSC curve of the diethylamine salt crystalline form A has two endothermic peaks at 104.3±10°C and 121.5±10°C, and in particular, the DSC curve of the diethylamine salt crystalline form A has two endothermic peaks at 104.3±5°C and 121.5±5°C.

[0025] In some embodiments, the diethylamine salt crystalline form A is (1) The TGA curve of the diethylamine salt crystalline form A has a weight loss of about 1.80% at 100.0±3°C and a weight loss of about 3.99% at 210.0±3°C; (2) The DSC curve of the diethylamine salt crystalline form A has one or two characteristics, that is, the DSC curve of the diethylamine salt crystalline form A has two endothermic peaks at 104.3±10°C and 121.5±10°C, and in particular, the DSC curve of the diethylamine salt crystalline form A has two endothermic peaks at 104.3±5°C and 121.5±5°C.

[0026] In some embodiments, the TGA pattern of the diethylamine salt crystalline form A is shown in FIG. 11, the DSC pattern of the diethylamine salt crystalline form A is shown in FIG. 1 The 1 H NMR spectrum is shown in FIG.

[0027] In some embodiments, the present invention provides a lysine salt crystalline form A of the compound of formula I, wherein the lysine salt crystalline form A has an X-ray powder diffraction pattern expressed at diffraction angles of 2θ±0.2° having diffraction peaks at 5.12, 10.44, 15.56, 18.07, 19.61, 21.10, 24.22, 32.97, and further wherein the lysine salt crystalline form A has an XRPD pattern essentially as shown in FIG. 14.

[0028] According to another aspect, the present invention provides methods for preparing the free acid crystalline form A of the compound of formula I above, comprising the following steps:

[0029] Method 1: The compound of formula I is added to an organic solvent I, which can be one or more combinations selected from ethyl acetate, dichloromethane, methyl tert-butyl ether, isopropanol, water, and volatilized at room temperature.

[0030] Method 2: The compound of formula I is crystallized in an organic solvent II, which can be one or more combinations selected from methanol, methyl ethyl ketone, isopropyl acetate, tetrahydrofuran, methyl tert-butyl ether, dimethylacetamide, by adding an anti-solvent, which can be one or more combinations selected from water, isopropyl ether, toluene, meta-xylene, 4-methylisopropylbenzene, n-pentane, n-heptane, cyclohexane, methylcyclohexane; if no precipitate is precipitated during stirring, add the anti-solvent to the system.

[0031] Method 3: The compound of formula I is suspended in an organic solvent III, which may be one or more combinations selected from n-pentane, toluene, meta-xylene, isopropyl ether, n-hexane, cyclohexane, methylcyclohexane, water, methanol, N,N-dimethylformamide, 2-methyltetrahydrofuran, acetone, methyl acetate, dichloromethane, and acetonitrile, at room temperature and stirred to crystallize.

[0032] Method 4: The compound of formula I is suspended in an organic solvent IV, which may be one or a combination of two or more selected from methylcyclohexane, isopropylbenzene, water, 1,4-dioxane, dimethylacetamide, tetrahydrofuran, n-hexane, 2-methyltetrahydrofuran, n-pentane, methyl ethyl ketone, isopropyl acetate, toluene, isobutanol, chloroform, and meta-xylene, at 40 to 60°C (for example, 50°C), and stirred to crystallize.

[0033] Method 5, the compound of formula I is crystallized by wet trituration in an organic solvent V, which can be one or more combinations selected from ethanol, dichloromethane, ethyl acetate, tetrahydrofuran.

[0034] According to another aspect, the present invention provides a method for preparing the free acid crystalline form B of the compound of formula I, comprising dissolving the free acid crystalline form A of the compound of formula I in an organic solvent B1 selected from ketones such as methyl ethyl ketone, methyl isopropyl ketone, acetone, diethyl ketone, dipropyl ketone, diisopropyl ketone, dibutyl ketone, diisobutyl ketone, etc., followed by gas-liquid diffusion in an atmosphere of an alkane organic compound, preferably a C1-C7 alkane organic compound, such as n-pentane, n-heptane, cyclohexane, to obtain the free acid crystalline form B of the compound of formula I. In some embodiments, the free acid crystalline form A of the compound of formula I is dissolved in MIBK (methyl isobutyl ketone), followed by gas-liquid diffusion in an atmosphere of n-pentane to obtain the free acid crystalline form B of the compound of formula I.

[0035] The present invention further provides a method for preparing a pharma- ceutically acceptable salt of a compound of formula I, comprising mixing a compound of formula I with a salt-forming agent (e.g., a corresponding base) in a suitable solvent. In some embodiments, the solvent is one or a combination of ethanol, heptane, ethyl acetate, MTBE, acetonitrile, water, and acetone.

[0036] According to a further aspect, the present invention provides pharmaceutical compositions comprising one or more of the free acid crystalline forms of the compound of formula I above (e.g., free acid crystalline form A, free acid crystalline form B), or pharma- ceutically acceptable salts of the compound of formula I (including crystalline forms thereof).

[0037] According to a further aspect, the present invention provides the use of a free acid crystalline form of the compound of formula I (e.g., free acid crystalline form A, free acid crystalline form B), a pharma- ceutically acceptable salt of the compound of formula I (including its crystalline form), or the pharmaceutical composition as described above, in the manufacture of a medicament for treating or preventing an EP4-related disease.

[0038] According to an embodiment of the present invention, the EP4-related disease includes at least one selected from inflammatory diseases, pain, cancer, metabolic diseases, and urinary system diseases, the inflammatory disease includes at least one selected from arthritis and rheumatoid arthritis, and the pain includes pain due to osteoarthritis and pain due to endometriosis.

[0039] According to an embodiment of the present invention, the free acid crystalline form of the compound of formula I (e.g., free acid crystalline form A, free acid crystalline form B), a pharma- ceutically acceptable salt of the compound of formula I (including its crystalline form) or the above pharmaceutical composition can be used in combination with radiation therapy and / or antibody therapy, wherein the antibody therapy is any one or combination of CTLA4 antibody therapy, PDL1 antibody therapy and PD1 antibody therapy.

[0040] According to embodiments of the invention, the cancer comprises a solid cancer. In some embodiments, the cancer comprises breast cancer, cervical cancer, colorectal cancer, endometrial cancer, spongioblastoma, head and neck cancer, kidney cancer, liver cancer, lung cancer, medulloblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, and urinary tract cancer.

[0041] According to an embodiment of the invention, the metabolic disease comprises diabetes and the urinary disease comprises overactive bladder.

[0042] According to an embodiment of the present invention, the use of a free acid crystalline form of the compound of formula I (e.g., free acid crystalline form A, free acid crystalline form B), a pharma- ceutically acceptable salt of the compound of formula I (including its crystalline form), or the above-mentioned pharmaceutical composition according to the present invention can provide a better and more effective clinical therapeutic agent or treatment regimen to a patient in need thereof.

[0043] The present invention also relates to a method for treating an EP4-related disease, comprising administering to a patient a therapeutically effective amount of a free acid crystalline form of the compound of formula I (e.g., free acid crystalline form A, free acid crystalline form B), a pharma- ceutically acceptable salt of the compound of formula I (including its crystalline form), or a pharmaceutical formulation comprising the pharmaceutical composition described above.

[0044] Definitions and Interpretations of Terms Unless otherwise specified, the definitions of groups and terms described in the specification and claims of this application, including their illustrative definitions, exemplary definitions, preferred definitions, definitions described in tables, definitions of specific compounds in the examples, etc., can be arbitrarily combined or combined with each other. The definitions of groups and the structures of compounds after such combination and combination should fall within the scope described in the specification of this application.

[0045] Unless otherwise specified, the numerical ranges described in the present specification and claims correspond to at least each specific integer value therein. For example, 2 or more means 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. When some numerical ranges are defined or understood as "numbers", it should be understood that the two end points of the range, each integer within the range, and each decimal within the range are described. For example, "numbers from 0 to 10" should be understood to describe not only each integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, but also the sum of each integer and 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 0.9 at least.

[0046] In the present specification and claims, when "about" is used in relation to a certain numerical value, it includes the numerical value itself, as well as numerical values ​​within a range around the numerical value that is acceptable in the art, such as numerical values ​​within ±15% of the numerical value, numerical values ​​within ±10% of the numerical value, numerical values ​​within ±5% of the numerical value, etc. For example, about 10 means that it includes numerical values ​​within the range of 10±1.5, i.e., within the range of 8.5 to 11.5, within the range of 10±1.0, i.e., within the range of 9.0 to 11.0, and within the range of 10±0.5, i.e., within the range of 9.5 to 10.5.

[0047] The term "patient" refers to any animal, including a mammal, preferably a mouse, rat, other rodent, rabbit, dog, cat, pig, cow, sheep, horse or primate, and most preferably a human.

[0048] The term "therapeutically effective amount" refers to an amount of an active compound or drug that elicits the biological or medical response that a researcher, veterinarian, physician, or other clinician is looking for in a tissue, system, animal, individual, or human, including one or more of the following: (1) disease prevention: e.g., prevention of a disease, disorder, or condition in an individual who is susceptible to the disease, disorder, or condition, but has not yet experienced or developed the pathology or symptoms of the disease; (2) disease inhibition: e.g., inhibition of a disease, disorder, or condition (i.e., prevention of further progression of the pathology and / or symptoms) in an individual who is experiencing or developing the pathology or symptoms of the disease, disorder, or condition; (3) disease mitigation: e.g., mitigation of a disease, disorder, or condition (i.e., reversal of the pathology and / or symptoms) in an individual who is experiencing or developing the pathology or symptoms of the disease, disorder, or condition.

[0049] The term "pharmaceutical acceptable" means that the formulation or active ingredient does not have undue adverse effects on the health of the general therapeutic target.

[0050] The term "pharmacologically acceptable excipient or carrier" refers to one or more compatible solid or liquid fillers or gel substances that must be suitable for human use and have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components of the composition can be mixed with the compounds of the present invention and with each other without appreciably reducing the efficacy of the compounds. Examples of pharmacologically acceptable excipient or carrier moieties include cellulose and its derivatives (sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oils (soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers, wetting agents (sodium lauryl sulfate, etc.), colorants, flavor enhancers, stabilizers, antioxidants, preservatives, pyrogen-free water, etc. Beneficial effects 1) The present invention provides crystalline forms of the compound of formula I with good pharmaceutical properties, of which the free acid crystalline form A has relatively low hygroscopicity and good physical and chemical stability, which is advantageous for drug storage, quality stability and further formulation.

[0051] 2) The present invention provides medicinal salts of the compound of formula I through optimization measurement screening, and further provides crystalline products of the salts, such as tromethamine salt crystalline form A, diethylamine salt crystalline form A, and lysine salt crystalline form A, among which tromethamine salt crystalline form A has relatively low hygroscopicity and good physical and chemical stability, higher solubility in biological solvents, and better pharmaceutical value. [Brief description of the drawings] FIG. 1 is an XRPD pattern of the free acid crystalline form A of the compound of formula I. [Figure 2] A TGA pattern of the free acid crystalline form A of the compound of formula I. [Figure 3] DSC pattern of the free acid crystalline form A of the compound of formula I. [Figure 4] Free acid crystalline form A of the compound of formula I 1 1 H NMR spectrum. [Figure 5] XRPD pattern of the free acid crystalline form B of the compound of formula I. [Figure 6] XRPD pattern of crystalline form A of the tromethamine salt of the compound of formula I. [Figure 7] A TGA pattern of crystalline form A of the tromethamine salt of the compound of formula I. [Figure 8] DSC pattern of crystalline form A of the tromethamine salt of the compound of formula I. [Figure 9] Crystalline form A of the tromethamine salt of compound of formula I 1 1 H NMR spectrum. [Figure 10] XRPD pattern of the diethylamine salt of the compound of formula I, crystalline form A. [Figure 11] A TGA pattern of crystalline form A of the diethylamine salt of the compound of formula I. [Figure 12] DSC pattern of crystalline form A of the diethylamine salt of the compound of formula I. [Figure 13] Crystalline form A of the diethylamine salt of the compound of formula I 1 1 H NMR spectrum. [Figure 14] XRPD pattern of crystalline form A of the lysine salt of the compound of formula I. [Figure 15] Dynamic solubility curve at 37°C. [Figure 16] XRPD overlay of a solubility sample of the free acid crystalline form A in HO.

[0033] FIG. 17 is an XRPD overlay of a solubility sample of the free acid crystalline form A in SGF.

[0033] FIG. 18 is an XRPD overlay of a solubility sample of the free acid form A in FaSSIF. [Figure 19] XRPD overlay of a solubility sample of free acid Form A in FeSSIF. [Figure 20] XRPD overlay of a solubility sample of tromethamine salt crystalline form A in SGF. [Figure 21] XRPD overlay of a solubility sample of tromethamine salt crystalline form A in FeSSIF. [Figure 22] DVS pattern of the free acid crystalline form A. [Figure 23] XRPD overlay of the free acid crystalline form A before and after DVS measurement. [Figure 24] DVS pattern of tromethamine salt crystal form A. [Figure 25] XRPD overlay of tromethamine salt crystalline form A before and after DVS measurement. [Figure 26] XRPD overlay of a stability evaluation sample of the free acid crystalline form A. [Figure 27] XRPD overlay of a stability evaluation sample of tromethamine salt crystalline form A. [Mode for carrying out the invention] The technical solution of the present invention will be described in more detail below with reference to specific examples. It should be understood that the following examples are merely illustrative and explanatory of the present invention and should not be construed as limiting the scope of the claims of the present invention. Any technology realized based on the above content of the present invention is included in the scope of the claims of the present invention.

[0052] Unless otherwise specified, all materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0053] The instruments and detection methods used in the present invention are as follows: 1. X-ray powder diffraction (XRPD) XRPD patterns were collected on a PANalytacal X-ray powder diffraction analyzer and the scan parameters are shown in Table A-1 below.

[0054] [Table 1]

[0055] 2. Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) TGA and DSC patterns were collected on a TA Q5000 / 5500 thermogravimetric analyzer and a TA Q2000 / 2500 differential scanning calorimeter, respectively, and the measurement parameters are listed in Table A-2 below.

[0056] [Table 2]

[0057] 3. Dynamic moisture sorption (DVS) Dynamic moisture sorption (DVS) curves were collected with a Surface Measurement Systems (SMS) DVS IntrInsic. Relative humidity at 25°C was corrected for the deliquescence points of LiCl, Mg(NO3)2, and KCl. DVS measurement parameters are listed in Table A-3 below.

[0058] [Table 3]

[0059] 4. Liquid nuclear magnetism ( 1 H NMR) Liquid state nuclear magnetic resonance spectra were collected on a Bruker 400M nuclear magnetic resonance instrument using CD3OD as the solvent.

[0060] 5. High performance liquid chromatography (HPLC) The purity, dynamic solubility and stability measurements were performed by Agilent 1260 high performance liquid chromatograph, and the analytical conditions are shown in Table A-4 below.

[0061] [Table 4]

[0062] The reagents used in the present invention are shown in Table A-5 below.

[0063] [Table 5]

[0064] Example 1 Preparation of Intermediate A

[0065] [ka]

[0066] At room temperature, the raw material 5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-formic acid (5 g, 23.8 mmol) (synthesized with reference to patent application WO2011151369A1) was added to DCM (dichloromethane) (200 mL), (S)-methyl 4-(1-aminoethyl)benzoate (5.1 g, 28.6 mmol), HATU (O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylurea hexafluorophosphate) (10.9 g, 28.6 mmol), DIPEA (N,N-diisopropylethylamine) (4.6 g, 35.7 mmol) were added, and the mixture was stirred at room temperature for 16 h, water (200 mL) was added, and DCM (50 The mixture was extracted with 10 mL of ethyl acetate (5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-formamide)ethyl)benzoic acid methyl ester (intermediate A) (5.6 g, yield 63.3%). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by separation using a silica gel column (petroleum ether:ethyl acetate (V / V) = 3:1) to obtain a white solid, (S)-4-(1-(5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-formamide)ethyl)benzoate methyl ester (intermediate A) (5.6 g, yield 63.3%).

[0067] LCMS (ESI) m / z: 372.5 [M+H] + Example 2 Preparation of Compounds of Formula I

[0068] [ka]

[0069] Step 1: 2-(3-(1,1-difluoroethyl)phenyl)pinacorborate (compound IB)

[0070] [ka]

[0071] 1-Bromo-3-(1,1-difluoroethyl)benzene (800 mg, 3.62 mmol) was added to 1,4-dioxane (30 mL) at room temperature, and pinacol diborate (17.0 g, 156.3 mmol), cuprous iodide (2.5 g, 13.0 mmol), L-proline (2.76 g, 10.86 mmol), potassium acetate (710 mg, 7.24 mmol), and [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride (295 mg, 0.36 mmol) were added. The mixture was heated to 90° C. under nitrogen gas protection and stirred for 16 h. The mixture was cooled to room temperature, diluted with water (200 mL), extracted with dichloromethane (80 mL×3), separated, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by separation on a silica gel column (pure petroleum ether) to obtain a colorless liquid crude product 2-(3-(1,1-difluoroethyl)phenyl)pinacorborate (compound IB) (900 mg, yield 92.7%).

[0072] Step 2: 3-(1,1-difluoroethyl)phenol (compound IC)

[0073] [ka]

[0074] 2-(3-(1,1-difluoroethyl)phenyl)pinacorborate (compound IB) (900 mg, 3.36 mmol) was added to THF (15 mL) and water (15 mL) at room temperature, sodium perborate monohydrate (1.01 g, 10.07 mmol) was added, and the mixture was stirred at room temperature for 16 h. Water (200 mL) was added to dilute the mixture, and the mixture was extracted with DCM (50 mL x 3), separated, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by separation using a silica gel column (petroleum ether: ethyl acetate (V / V) = 8: 1) to obtain colorless liquid 3-(1,1-difluoroethyl)phenol (compound IC) (280 mg, yield 52.7%).

[0075] Step 3: (S)-4-(1-(5-(3-(1,1-difluoroethyl)benzyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-formamido)ethyl)methyl benzoate (Compound ID)

[0076] [ka]

[0077] Compound (S)-4-(1-(5-chloro-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-formamido)ethyl)methyl benzoate (Intermediate A) (650 mg, 1.75 mmol) was added to DMF (12 mL) at room temperature, 3-(1,1-difluoroethyl)phenol (IC) (360 mg, 2.27 mmol) and potassium hydroxide (147 mg, 2.62 mmol) were added, and the mixture was heated to 120° C. and stirred for 2 h. The mixture was cooled to room temperature, diluted with water (200 mL), extracted with ethyl acetate (80 mL×3), separated, and the organic phases were combined. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a colorless liquid crude product, methyl (S)-4-(1-(5-(3-(1,1-difluoroethyl)benzyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-formamide)ethyl)benzoate (Compound ID) (1.2 g, crude product).

[0078] LCMS (ESI) m / z: 494.6 [M+H] + .

[0079] Step 4: (S)-4-(1-(5-(3-(1,1-difluoroethyl)benzyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-formamido)ethyl))benzoic acid (compound I)

[0080] [ka]

[0081] At room temperature, the raw material (S)-4-(1-(5-(3-(1,1-difluoroethyl)benzyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-formamide)ethyl)methyl benzoate (compound ID) (1.0 g, 2.03 mmol) was added to THF (5 mL), water (4 mL), and lithium hydroxide monohydrate (340 mg, 8.11 mmol) were added, and the mixture was stirred at room temperature for 16 h. The reaction solution was concentrated to produce a white solid (S)-4-(1-(5-(3-(1,1-difluoroethyl)benzyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-formamide)ethyl))benzoic acid (compound I) (88 mg, yield 7.9%).

[0082] LCMS (ESI) m / z: 480.5 [M+H] + 1 H NMR (400m Hz, DMSO-d6) δ12.8 (s, 1H), 8.10 (d, 1H), 7.71 (d, 2H), 7.53 (t, 1H), 7.47 (d, 1H), 7.27 (d, 1H), 7.11 (t, 1H), 7.11 (d, 2H), 7.07 (dd, 1H), 4.88 (t, 1H), 3.74 (s, 3H), 1.96 (t, 3H), 1.96 (d, 3H). Example 3 Preparation of the free acid crystalline form A of the compound of formula I The compound of formula I prepared according to the method of Example 2 was dissolved in a mixed solvent of dichloromethane and n-hexane (1:10, v / v), and after concentration, the free acid crystalline form A of the compound of formula I was obtained.

[0083] The XRPD of the obtained free acid crystalline form A of the compound of formula I is shown in Figure 1. The TGA / DSC results (Figures 2-3) showed that when the sample was heated to 150°C, it had a weight loss of 0.84% ​​and had one endothermic peak at 136.8±3°C. 1 The H NMR results are shown in Figure 4. Because the free acid crystalline form A had a relatively low TGA weight loss and only a single melting endotherm signal in the DSC, it was inferred to be an anhydrous crystalline form.

[0084] The XRPD analysis data of the obtained free acid crystalline form A of the compound of formula I is shown in Table 3-1 below.

[0085] [Table 6] JPEG2024537564000016.jpg72169

[0086] Example 4 Preparation of the free acid crystalline form B of the compound of formula I The free acid crystalline form A was dissolved in MIBK (methyl isobutyl ketone) until transparent, and then subjected to gas-liquid diffusion in an n-pentane atmosphere to obtain the XRPD pattern shown in FIG. 5.

[0087] The free acid crystalline form B was dried at room temperature and then converted to the free acid crystalline form A.

[0088] The XRPD analysis data of the obtained free acid crystalline form B of the compound of formula I is shown in Table 4-1 below.

[0089] [Table 7]

[0090] Example 5 Preparation and Screening of Salt Forms of Compounds of Formula I Approximately 20 mg of the starting free acid crystalline form A sample and an equimolar amount of the salt-forming formulation (i.e., the base that forms a salt with the free acid) were weighed into an HPLC vial, 0.5 mL of solvent was added and mixed to obtain a suspension, and the salt-forming formulation was first diluted with the corresponding solvent and then mixed with the starting sample. After suspension and stirring at room temperature for about 3 days, the solid was separated by centrifugation and vacuum dried at room temperature overnight. In the case of the colloid-forming system at room temperature, crystallization was induced by circulating heating and cooling at a temperature set to 50-5°C, and in the case of the clear system at room temperature, crystallization was induced with stirring at a temperature set to 5°C or -20°C. The obtained solid XRPD characterization results showed that a total of three salt forms were obtained in the salt type screening measurement (shown in Table 5-1 below).

[0091] [Table 8] JPEG2024537564000019.jpg210169

[0092] Example 6 Preparation of Crystalline Form A of the Tromethamine Salt of Compound of Formula I After the free acid crystalline form A and an equimolar amount of tromethamine were slurried with MTBE at room temperature for 3 days, the solid was separated by centrifugation and dried under vacuum at room temperature to obtain tromethamine salt crystalline form A of compound of formula I.

[0093] The XRPD pattern of a sample of tromethamine salt crystalline form A is shown in Figure 6. The TGA / DSC results were listed in Figures 7-8. The TGA results showed that the sample had a weight loss of 2.41% when heated to 120°C, and the DSC results showed that the sample had one endothermic peak at 139.2°C (peak value temperature). 1 H NMR was measured by CD3OD and the results are shown in Figure 9. The results showed that in the tromethamine salt crystalline form A, the molar ratio of tromethamine to free acid was 1:1, and no residual MTBE solvent was observed.

[0094] The XRPD analysis data of the obtained crystalline form A of the tromethamine salt of the compound of formula I is shown in Table 6-1 below.

[0095] [Table 9]

[0096] Example 7 Preparation of Crystalline Form A of the Diethylamine Salt of Compound of Formula I A sample of the free acid crystalline form A and an equimolar amount of diethylamine were slurried in MTBE at room temperature for 3 days, after which the solid was separated by centrifugation and dried under vacuum at room temperature to obtain diethylamine salt crystalline form A of compound of formula I.

[0097] The XRPD pattern of a sample of diethylamine salt crystalline form A is shown in Figure 10. The TGA / DSC results are detailed in Figures 11-12. The TGA results showed that the sample had a weight loss of 1.80% when heated to 100.0°C and a weight loss of 3.99% when heated from 100.0°C to 210.0°C, and the DSC results showed that the sample had two endothermic peaks at 104.3°C and 121.5°C (peak value temperatures). 1 H NMR was measured by CD3OD and the results are shown in Figure 13. The results showed that in the diethylamine salt crystalline form A, the molar ratio of diethylamine to free acid was 1:1, and no residual MTBE solvent was observed.

[0098] The XRPD analysis data of the obtained diethylamine salt crystalline form A of the compound of formula I is shown in Table 7-1 below.

[0099] [Table 10]

[0100] Example 8 Preparation of Crystalline Form A of the Lysine Salt of Compound of Formula I A sample of the free acid crystalline form A and an equimolar amount of lysine were slurried with EtOAc at room temperature for 3 days, and the solid was separated by centrifugation and dried under vacuum at room temperature to obtain the lysine salt crystalline form A of the compound of formula I. The sample was characterized by XRPD (see FIG. 14).

[0101] The XRPD analysis data of the obtained lysine salt crystalline form A of the compound of formula I is shown in Table 8-1 below.

[0102] [Table 11]

[0103] Example 9 Dynamic Solubility Experiments The solid input concentration was 10 mg / mL (40 mg of solid as free acid was input into 4 mL of solvent) and mixed by rotation at 37°C, and the solubility of each sample was measured in four systems, water, SGF, FaSSIF and FeSSIF, at different time points (1, 2, 4 and 24 hours). After sampling at each time point, the samples were filtered (0.45 μm PTFE filter head) by centrifugation (10000 rpm), the HPLC concentration and pH value of the filtrate were measured, and XRPD was measured for the solid sample after centrifugation. The solubility measurement results are summarized in Table 9-1, the solubility curve is shown in Figure 15, and the XRPD results of the samples after solubility measurement are shown in Figures 16-21. The results showed that the solubility of tromethamine salt crystalline form A in different solvents was superior to that of the free acid crystalline form A, the crystalline form of the free acid crystalline form A did not change after the solvent solubility measurement, and the tromethamine salt crystalline form A was converted to the free acid crystalline form A in SGF and FeSSIF after the solubility measurement.

[0104] [Table 12]

[0105] Biological Solvent Preparation Instructions: Preparation of simulated gastric fluid (SGF) 200.3 mg of NaCl and 105.0 mg of Trianaton X-100 were weighed and placed in a 50 mL flask, and purified water was added until the mixture became clear. 136 μL of concentrated hydrochloric acid (12 M) was added, and the pH was adjusted to 1.8 with 1 M hydrochloric acid or 1 M NaOH solution. The volume was then adjusted to the constant level with purified water.

[0106] Preparation of intestinal fluid simulating fasting state (FaSSIF) 0.34 g of anhydrous NaH2PO4, 0.44 g of NaOH, and 0.62 g of NaCl were weighed into a 50 mL flask. Purified water was added until clear, and the pH was adjusted to 6.5 with 1 M hydrochloric acid or 1 M NaOH solution. Purified water was added to volume, and 0.11 g of SIF powder was weighed and dissolved until clear.

[0107] Preparation of intestinal fluid simulating fed state (FeSSIF) 0.82 mL of glacial acetic acid, 0.40 g of NaOH, and 1.19 g of NaCl were placed in a 50 mL flask. Approximately 48 mL of purified water was added until clear, and the pH was adjusted to 5.0 with 1 M hydrochloric acid or 1 M NaOH solution. Purified water was added to volume, and 0.56 g of SIF powder was weighed and dissolved until clear.

[0108] Example 10 Hygroscopicity The hygroscopicity of the free acid crystalline form A and the tromethamine salt crystalline form A was evaluated by dynamic moisture sorption apparatus (DVS). Starting from 0% RH, the percentage mass change of the samples was collected at a constant temperature of 25°C during the measurement as the humidity changed (0% RH-95% RH-0% RH). The DVS measurement results and the XRPD results before and after the DVS measurement are shown in Figures 22-25. The results show that the moisture adsorption of the free acid crystalline form A sample at 25°C / 80% RH was 0.07%, indicating almost no hygroscopicity, and the weight of the tromethamine salt crystalline form A sample at 25°C / 80% RH was 0.6%, indicating slight hygroscopicity. The crystal forms of the free acid crystalline form A and the tromethamine salt crystalline form A samples did not change after the DVS measurement.

[0109] Example 11 Solid state stability After the free acid crystalline form A and the tromethamine salt crystalline form A were respectively stored in an open state for 1 / 4 week under the conditions of 25℃ / 60%RH and 40℃ / 75%RH, the physical and chemical stability of the samples were detected by XRPD and HPLC. The purity data are listed in Table 11-1, and the XRPD results are listed in Figures 26-27. The results show that the HPLC purity of the free acid crystalline form A and the tromethamine salt crystalline form A did not change obviously after being stored under the corresponding conditions, and the crystal form did not change.

[0110] [Table 13]

[0111] Example 12 Different processes for preparing the free acid crystalline form A of the compound of formula I The compound of formula I can be prepared according to the process method of Example 2, and the free acid crystalline form A (identified by XRPD) can also be prepared according to the following method.

[0112] 12.1 20 mg of the compound of formula I was added to a 5 mL vial, and 0.4-1.0 mL of a solvent was added to each vial. After dissolving, the solution was filtered, the vial was sealed with a sealing film, and two pinholes were pierced, and the solution was allowed to evaporate slowly at room temperature, and the solid obtained was collected. The solvent was one selected from ethyl acetate, dichloromethane, methyl tert-butyl ether, and isopropanol / water (3:1).

[0113] 12.2 Add 20 mg of compound of formula I to a 20 mL vial, add 0.4-1.0 mL of solvent respectively, add anti-solvent (about 5 mL, add anti-solvent dropwise to the clear solution with stirring (1000 rpm) until solids are precipitated, or after the total volume of added anti-solvent reaches 5 mL, suspend and stir the sample without precipitated solids at 5°C, if still no solids are precipitated, suspend and stir at -20°C, and evaporate the final clear sample at room temperature) to the clear solution with stirring (1000 rpm) until solids are precipitated, and collect the resulting solids. When the dissolving solvent is methanol, the anti-solvent is water; when the dissolving solvent is methyl ethyl ketone, the anti-solvent is 4-isopropyltoluene or n-heptane; when the dissolving solvent is isopropyl acetate, the anti-solvent is cyclohexane or meta-xylene; when the dissolving solvent is selected from tetrahydrofuran, the anti-solvent is water or toluene; when the dissolving solvent is selected from methyl tert-butyl ether, the anti-solvent is methylcyclohexane; when the dissolving solvent is selected from dimethylacetamide, the anti-solvent is selected from water.

[0114] 12.3 20 mg of the compound of formula I was completely dissolved in 0.4-0.6 mL of solvent. The clear solution was added dropwise to 5 mL of anti-solvent with stirring (1000 rpm), and the precipitated solid was collected. The dissolving solvent was one of isopropanol, ethyl acetate, or 2-methyltetrahydrofuran, the anti-solvent was n-heptane, the dissolving solvent was one of acetone, tert-butyl acetate, or chloroform, the anti-solvent was toluene, and the dissolving solvent was acetonitrile, the anti-solvent was water.

[0115] 12.4 Approximately 20-90 mg of the compound of formula I was weighed into an HPLC glass vial, 0.5 mL of solvent was added to each, and the resulting suspension was magnetically stirred (1000 rpm) at room temperature for about 4 days, and then centrifuged (10000 rpm, 2 min) to collect the solid. The solvent was one selected from n-pentane, meta-xylene, isopropyl ether, cyclohexane, water, methanol / water (1:5), N,N-dimethylformamide / water (1:4), 2-methyltetrahydrofuran / n-hexane (1:5), acetone / n-heptane (1:4), anisole / n-heptane (1:4), methyl acetate / cyclohexane (1:4), methanol / 4-isopropyltoluene (1:4), dichloromethane / methyl n-hexane (1:5), and acetonitrile / toluene (1:4).

[0116] 12.5 Approximately 20-50 mg of the compound of formula I was weighed into an HPLC glass vial, 0.5 mL of solvent was added to each, and the resulting suspension was magnetically stirred (1000 rpm) at 50°C for about 3 days, and then centrifuged (10000 rpm, 2 min) to collect the solid. The solvent was one selected from methylcyclohexane, isopropylbenzene, water, 1,4-dioxane / water (1:9), dimethylacetamide / water (1:9), tetrahydrofuran / n-hexane (1:9), 2-methyltetrahydrofuran / cyclohexane (1:4), cyclopentyl methyl ether / n-pentane (1:4), methyl ethyl ketone / isopropylbenzene (1:7), isopropyl acetate / toluene (1:9), isobutanol / 4-isopropyltoluene (1:4), and chloroform / metaxylene (1:4).

[0117] 12.6 Approximately 20 mg of the compound of formula I was weighed into an HPLC glass vial, 0.5 mL of solvent was added to each, and the resulting suspension was magnetically stirred (1000 rpm) with temperature cycling (50-5°C, 0.1°C / min, two cycles), and centrifuged (10000 rpm, 2 min) to collect the solid. The solvent was one selected from toluene, n-heptane, 4-isopropyltoluene, ethanol / water (1:4), ethyl acetate / methylcyclohexane (1:9), cyclopentyl methyl ether / n-hexane (1:3), chloroform / n-heptane (1:7), and methyl ethyl ketone / metaxylene (1:9).

[0118] 12.7 Approximately 20 mg of the compound of formula I was weighed into a grinding bowl, 0.2 mL of a solvent was added, the sample was ground for 2-3 minutes, and the solid was collected. The solvent is one selected from ethanol, dichloromethane, ethyl acetate, and tetrahydrofuran.

[0119] The above describes the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention are intended to be included in the scope of the claims of the present invention. [Brief description of the drawings]

[0120] [Figure 1] 1 is an XRPD pattern of the free acid crystalline form A of the compound of formula I. [Diagram 2] 1 is a TGA pattern of the free acid crystalline form A of the compound of formula I. [Diagram 3] 1 is a DSC pattern of the free acid crystalline form A of the compound of formula I. [Figure 4] 1 is a 1H NMR spectrum of the free acid crystalline form A of the compound of formula I. [Diagram 5] 1 is an XRPD pattern of the free acid crystalline form B of the compound of formula I. [Figure 6] 1 is an XRPD pattern of crystalline form A of the tromethamine salt of compound of formula I. [Figure 7] 1 is a TGA pattern of crystalline form A of the tromethamine salt of compound of formula I. [Figure 8] 1 is a DSC pattern of crystalline form A of the tromethamine salt of compound of formula I. [Figure 9] 1 is a 1H NMR spectrum of the tromethamine salt of the compound of formula I, Form A. [Figure 10] 1 is an XRPD pattern of the diethylamine salt of the compound of formula I, crystalline form A. [Figure 11] 1 is a TGA pattern of the diethylamine salt of the compound of formula I, crystalline form A. [Figure 12] 1 is a DSC pattern of the diethylamine salt of the compound of formula I, crystalline form A. [Figure 13] 1 is a 1H NMR spectrum of the diethylamine salt of the compound of formula I, crystalline form A. [Figure 14] 1 is an XRPD pattern of crystalline form A of the lysine salt of the compound of formula I. [Figure 15] FIG. 2 is a kinetic solubility curve at 37° C. [Figure 16] 1 is an XRPD overlay of a solubility sample of the free acid form A in HO. [Figure 17] 1 is an XRPD overlay of a solubility sample of the free acid form A in SGF. [Figure 18]1 is an XRPD overlay of a solubility sample of free acid Form A in FaSSIF. [Figure 19] FIG. 13 is an XRPD overlay of a solubility sample of free acid Form A in FeSSIF. [Figure 20] 1 is an XRPD overlay of a solubility sample of tromethamine salt crystalline form A in SGF. [Figure 21] FIG. 1 is an XRPD overlay of a solubility sample of tromethamine salt crystalline form A in FeSSIF. [Figure 22] 1 shows the DVS pattern of the free acid crystalline form A. [Figure 23] 1 is an XRPD overlay of the free acid form A before and after DVS measurement. [Figure 24] 1 shows the DVS pattern of tromethamine salt crystalline form A. [Diagram 25] 1 is an XRPD overlay of tromethamine salt crystalline form A before and after DVS measurement. [Figure 26] 1 is an XRPD overlay of a stability assessment sample of the free acid crystalline form A. [Figure 27] 1 is an XRPD overlay of a stability evaluation sample of tromethamine salt crystalline form A.

Claims

1. The structure of the compound is shown below: A crystalline form of the compound of formula I, characterized in that 【Chemistry 1】

2. The crystalline form is free acid crystalline form A of the compound of formula I, and the X-ray powder diffraction pattern of the free acid crystalline form A expressed at diffraction angles of 2θ±0.2° has diffraction peaks at 7.88, 11.00, 12.13, 16.10, 19.75, 20.65, 21.04, 22.92, 23.53 and 26.69; or the X-ray powder diffraction pattern of the free acid crystalline form A expressed at diffraction angles of 2θ±0.2° has diffraction peaks at 7.88, 8.08, and the X-ray powder diffraction pattern of the free acid crystalline form A, expressed as diffraction peaks at 2θ±0.2° diffraction angles, is 7.88, 8.08, 11.00, 12.13, 13.59, 15.50, 16.10, 19.44, 19.75, 20.65, 21.04, 22.92, 23.53, 25.32, 26.44, 26.69, 27.06, 28.05, 29.04, 30.06, 31.06, 32.06, 33.06, 34.06, 35.06, 36.06, 37.06, 38.06, 39.06, 40.06, 41.06, 42.06, 43.06, 44.06, 45.06, 46.06, 47.06, 48.06, 50.06, 51.06, 52.06, 53.06, 54.06, 55.06, 56.06, 57.06, 58.06, 59.06, 60.06, 61.06, 62.06, 63.06, 64.06, 65.06, 66.06, 67.06, 68.06, 70.06, 71.06, 72.06, 73.06, 74.06, 75.06, 76.06, 77.06, 78.06, 79.06, 80.06, 8 and 7.67, and further, the X-ray powder diffraction pattern of the free acid crystalline form A, represented by diffraction angles 2θ±0.2°, is 7.88, 8.08, 10.31, 10.49, 11.00, 11.46, 12.13, 12.82, 13.59, 15.29, 15.50, 15.72, 16.10, 18.27, 18.70, 19.04, 19.44, 19.75, 20.65, 21.04, 21.62, 21.97, 22.06, 23.05, 24.04, 25.09, 26.06, 27.08, 28.09, 29.08, 30.06, 31.04, 32.09, 33.09, 34.09, 35.09, 36.09, 37.09, 38.09, 39.09, 40.09, 41.09, 42.09, 43.09, 44.09, 45.09, 46.09, 47.09, 48.09, 49.09, 50.09, 51.09, 52.09, 53.09, 54.09, 55.09, 56.09, 57.09, 58.09, 59.09, 60.09, 61.09, 62.09, 63.09, 64.09, 65.09, 66.09, 67. 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 22.92, 23.53, 24.22, 25.32, 25.81, 26.21, 26.44, 26.69, 27.67, 28.99, 29.35, 30.17, 31.12, 31.65, 32.18, 33.44, 33.97, 35.78, 36.84, 37.18, 37.99; and further, the free acid crystalline form A has an XRPD pattern essentially as shown in FIG. Preferably, the free acid crystalline form A is (1) The TGA curve of the free acid crystalline form A has a weight loss of about 0-2%, preferably about 0-1% (e.g., 0.84%) at 150.0±3° C. (2) The DSC curve of the free acid crystalline form A has an endothermic peak at 134.0±3°C. (3) The DSC curve of the free acid crystalline form A has one, two or three characteristics, such as an endothermic peak at 136.8±3°C. A crystalline form of the compound of formula I according to claim 1, characterized in that

3. The crystalline form is free acid crystalline form B of the compound of formula I, and the X-ray powder diffraction pattern of the free acid crystalline form B expressed at 2θ±0.2° diffraction angles has diffraction peaks at 7.38, 8.91, 11.07, 17.85, 18.52, 19.38, 23.05, 26.01, 26.76; and the X-ray powder diffraction pattern of the free acid crystalline form B expressed at 2θ±0.2° diffraction angles has diffraction peaks at 7.38, 8.91, 11.07, 12.01, 17.85, 18.52, 19.38, 23.05, 26.01, 26.76; and the X-ray powder diffraction pattern of the free acid crystalline form B expressed at 2θ±0.2° diffraction angles has diffraction peaks at 5.56, 6.00, 7.38, 8.91, 11.07, and further, the X-ray powder diffraction pattern of the free acid crystalline form B, expressed as diffraction peaks at 2θ±0.2° diffraction angles, is 5.56, 6.00, 7.38, 8.01, 9.02, 10.05, 11.58, 12.01, 13.58, 14.16, 14.78, 17.85, 18.52, 19.38, 22.33, 23.05, 24.64, 26.01, and 26.

76. and wherein the free acid crystalline form B has diffraction peaks at: 27, 8.91, 11.07, 11.58, 12.01, 13.58, 14.16, 14.78, 15.73, 17.85, 18.52, 19.38, 22.33, 23.05, 24.64, 26.01, 26.76; and further wherein the free acid crystalline form B has an XRPD pattern essentially as shown in FIG. A crystalline form of the compound of formula I according to claim 1, characterized in that

4. A pharma- ceutically acceptable salt of a compound of formula I or a crystalline form thereof, The pharma- ceutically acceptable salt is selected from the salts formed by the compounds of formula I with alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), ammonium salts, or organic bases providing a physiologically acceptable cation, such as, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide, betaine, monoethanolamine, caffeine, urea, nicotinamide, isonicotine, dimethylglucosamine, ethylglucosamine, glucosamine, meglumine, lysine, arginine, choline, aqueous ammonia, dicyclohexylamine, 1,6-hexanediamine, ethanolamine, diethanolamine, sarcosine, and serinol. , trihydroxymethylaminomethane, aminopropylene glycol, tromethamine, diethylamine, imidazole and the like. Preferably, the pharma- ceutically acceptable salts of the compound of formula I are the tromethamine salt, the diethylamine salt and the lysine salt of the compound of formula I, the structure of the compound of formula I being as shown below: A pharma- ceutically acceptable salt of a compound of formula I or a crystalline form thereof, characterized in that: 【Chemistry 2】

5. The crystalline form is tromethamine salt crystalline form A of the compound of formula I, and the X-ray powder diffraction pattern of the tromethamine salt crystalline form A expressed at a diffraction angle of 2θ±0.2° has diffraction peaks at 6.03, 9.01, 13.50, 15.06, 18.09, and 24.27, and the X-ray powder diffraction pattern of the tromethamine salt crystalline form A expressed at a diffraction angle of 2θ±0.2° has diffraction peaks at 6.03, 9.01, 13.50, 15.06, 16.03, 18.09, 24.27, 27.28, 30.39, and 36.72, and the tromethamine salt crystalline form A has an XRPD pattern essentially as shown in FIG. 6, and preferably, the tromethamine salt crystalline form A is (1) The TGA curve of the tromethamine salt crystalline form A has a weight loss of about 1.0-3.5%, preferably about 2.0-3.0% (e.g., 2.41%) at 120.0±3°C; (2) The DSC curve of tromethamine salt crystalline form A has an endothermic peak at 124.5±3°C. (3) The DSC curve of the tromethamine salt crystalline form A has one, two or three characteristics, such as an endothermic peak at 139.2±3°C; More preferably, the TGA pattern of the tromethamine salt crystalline form A is shown in FIG. 7, the DSC pattern of the tromethamine salt crystalline form A is shown in FIG. 1 The H NMR spectrum is shown in FIG. A crystalline form of a pharma- ceutically acceptable salt of the compound of formula I according to claim 4.

6. The crystalline form is diethylamine salt crystalline form A of the compound of formula I, and the X-ray powder diffraction pattern of the diethylamine salt crystalline form A expressed at a diffraction angle of 2θ±0.2° has diffraction peaks at 5.29, 9.79, 10.53, 18.30, 19.61, 19.99, 21.10, 25.33, and 26.

45. Furthermore, the X-ray powder diffraction pattern of the diethylamine salt crystalline form A expressed at a diffraction angle of 2θ±0.2° has diffraction peaks at 5.29, 9.79, 10.53, 18.30, 19.61, 19.99, 21.10, 25.33, and 26.

45. and further, the diethylamine salt crystalline form A has diffraction peaks at: 1.53, 11.20, 12.52, 14.85, 15.20, 16.22, 16.86, 18.30, 19.61, 19.99, 21.10, 22.12, 22.47, 24.57, 24.85, 25.33, 26.45, 27.39, 28.01, 29.61, 32.13, 35.00 and 37.44; and further, the diethylamine salt crystalline form A has an XRPD pattern essentially as shown in FIG. 10 . Preferably, the diethylamine salt crystalline form A is (1) The TGA curve of the diethylamine salt crystalline form A has a weight loss of about 0.50-3.00%, preferably about 1.00-2.50% (e.g., 1.80%) at 100.0±3°C, and a weight loss of about 2.00-5.00%, preferably about 3.00-4.50% (e.g., 3.99%) at 210.0±3°C. (2) The DSC curve of the diethylamine salt crystalline form A has two endothermic peaks at 104.3±10°C and 121.5±10°C, and in particular, the DSC curve of the diethylamine salt crystalline form A has two endothermic peaks at 104.3±5°C and 121.5±5°C. More preferably, the TGA pattern of the diethylamine salt crystalline form A is shown in FIG. 11, the DSC pattern of the diethylamine salt crystalline form A is shown in FIG. 1 The H NMR spectrum is shown in FIG. A crystalline form of a pharma- ceutically acceptable salt of the compound of formula I according to claim 4.

7. The crystalline form is lysine salt Form A of the compound of formula I, and the X-ray powder diffraction pattern of the lysine salt Form A expressed at diffraction angles of 2θ±0.2° has diffraction peaks at 5.12, 10.44, 15.56, 18.07, 19.61, and 21.10; and the X-ray powder diffraction pattern of the lysine salt Form A expressed at diffraction angles of 2θ±0.2° has diffraction peaks at 5.12, 10.44, 15.56, 18.07, 19.61, 21.10, 24.22, and 32.97; and the lysine salt Form A has an XRPD pattern essentially as shown in FIG.

14. A crystalline form of a pharma- ceutically acceptable salt of the compound of formula I according to claim 4.

8. A method for preparing the free acid crystalline form A of the compound of formula I according to claim 2, comprising the steps of: Method 1: Adding the compound of formula I to an organic solvent I, which may be one or more combinations selected from ethyl acetate, dichloromethane, methyl tert-butyl ether, isopropanol, water, and volatilizing at room temperature; Method 2: crystallize the compound of formula I in an organic solvent II, which may be one or more combinations selected from methanol, methyl ethyl ketone, isopropyl acetate, tetrahydrofuran, methyl tert-butyl ether, dimethylacetamide, by adding an anti-solvent, which may be one or more combinations selected from water, isopropyl ether, toluene, meta-xylene, 4-methylisopropylbenzene, n-pentane, n-heptane, cyclohexane, methylcyclohexane; if no precipitate is precipitated during stirring, add an anti-solvent to the system; Method 3: The compound of formula I is suspended in an organic solvent III, which may be one or more combinations selected from n-pentane, toluene, meta-xylene, isopropyl ether, n-hexane, cyclohexane, methylcyclohexane, water, methanol, N,N-dimethylformamide, 2-methyltetrahydrofuran, acetone, methyl acetate, dichloromethane, acetonitrile, at room temperature and stirred to crystallize; Method 4: The compound of formula I is suspended in an organic solvent IV, which may be one or more combinations selected from methylcyclohexane, isopropylbenzene, water, 1,4-dioxane, dimethylacetamide, tetrahydrofuran, n-hexane, 2-methyltetrahydrofuran, n-pentane, methyl ethyl ketone, isopropyl acetate, toluene, isobutanol, chloroform, and meta-xylene, at 40-60° C. (e.g., 50° C.) and stirred to crystallize; Method 5: The compound of formula I is crystallized by wet grinding in an organic solvent V, which may be one or more combinations selected from ethanol, dichloromethane, ethyl acetate, tetrahydrofuran; A manufacturing method comprising the steps of:

9. A method for preparing the free acid crystalline form B of the compound of formula I according to claim 3, comprising the steps of: The method includes the steps of dissolving the free acid crystalline form A of the compound of formula I in an organic solvent B1 selected from ketones such as methyl ethyl ketone, methyl isopropyl ketone, acetone, diethyl ketone, dipropyl ketone, diisopropyl ketone, dibutyl ketone, diisobutyl ketone, and the like, and then subjecting the solution to gas-liquid diffusion in an atmosphere of an alkane-based organic compound, preferably a C1-C7 alkane-based organic compound, such as n-pentane, n-heptane, cyclohexane, and the like, and preferably dissolving the free acid crystalline form A of the compound of formula I in MIBK (methyl isobutyl ketone), and then subjecting the solution to gas-liquid diffusion in an atmosphere of n-pentane to obtain the free acid crystalline form B of the compound of formula I. A manufacturing method comprising:

10. A process for preparing a pharma- ceutically acceptable salt of a compound of formula I according to any one of claims 4 to 7 or a crystalline form thereof, comprising the steps of: The method includes the step of mixing the compound of formula I with a salt-forming agent (e.g., a corresponding base) in a suitable solvent, preferably the solvent is one or a combination of more selected from ethanol, heptane, ethyl acetate, MTBE, acetonitrile, water, and acetone; A manufacturing method comprising:

11. 1. A pharmaceutical composition comprising: The present invention relates to a compound of formula I, comprising one or more of the following: a crystalline form of the compound of formula I according to any one of claims 1 to 7; a pharma- ceutically acceptable salt of the compound of formula I; or a crystalline form thereof. A pharmaceutical composition comprising:

12. Use of a crystalline form of the compound of formula I according to any one of claims 1 to 7, a pharma- ceutically acceptable salt of the compound of formula I or a crystalline form thereof in the manufacture of a medicament for treating or preventing an EP4-related disease; Preferably, The EP4-related disease includes at least one selected from inflammatory diseases, pain, cancer, metabolic diseases, and urinary diseases, the inflammatory disease includes at least one selected from arthritis and rheumatoid arthritis, and the pain includes pain due to osteoarthritis and pain due to endometriosis; Preferably, The crystalline form of the compound of formula I, the pharma- ceutically acceptable salt of the compound of formula I or a crystalline form thereof or a pharmaceutical composition can be used in combination with radiation therapy and / or antibody therapy, wherein the antibody therapy is any one or combination of CTLA4 antibody therapy, PDL1 antibody therapy and PD1 antibody therapy.

13. Use of the pharmaceutical composition of claim 11 in the manufacture of a medicament for treating or preventing an EP4-related disease. Preferably, The EP4-related disease includes at least one selected from inflammatory diseases, pain, cancer, metabolic diseases, and urinary diseases, the inflammatory disease includes at least one selected from arthritis and rheumatoid arthritis, and the pain includes pain due to osteoarthritis and pain due to endometriosis; Preferably, The crystalline form of the compound of formula I, the pharma- ceutically acceptable salt of the compound of formula I or a crystalline form thereof or a pharmaceutical composition can be used in combination with radiation therapy and / or antibody therapy, wherein the antibody therapy is any one or combination of CTLA4 antibody therapy, PDL1 antibody therapy and PD1 antibody therapy.